[Multiple prostatic biopsies in the "gray zone" of the specific prostatic antigen]

Prior research has shown that prostate-specific antigen (PSA) levels between 4 and 10 ng/mL represent a diagnostic gray zone. Established knowledge includes the use of digital rectal exams and transrectal ultrasound to detect prostate abnormalities. However, these methods may miss tumors in patients with normal findings. No prior work had resolved how to improve cancer detection in this gray zone. This gap motivated the current study. Researchers propose that random biopsies may detect tumors undetected by imaging or physical exams. The gray zone remains a challenge for clinicians. Patients with normal exams but elevated PSA still face cancer risk. The need for better diagnostic strategies persists.

The aim of this study was to evaluate whether prostatic cancer could be detected in patients with normal digital exams and transrectal ultrasound findings but PSA levels between 4 and 10 ng/mL. The specific problem is the uncertainty of diagnostic accuracy in the gray zone. Motivation comes from the clinical need to avoid missing cancers in this group. The researchers propose that random biopsies may detect tumors not visible on imaging. This approach could improve diagnostic sensitivity. The study focuses on a narrow PSA range to test biopsy effectiveness. The goal is to confirm the value of biopsies in this diagnostic gap.

The study included 290 patients who underwent transrectal ultrasound and random bilateral biopsies. Six samples were collected using 16-Gauge needles from each side of the prostate. Inclusion criteria required PSA values between 4 and 10 ng/mL and normal digital and ultrasound findings. A subset of 34 patients was selected for detailed analysis. Blood samples were collected every 30 days for PSA velocity calculations. Biopsy results were categorized as cancer, prostatitis, or benign prostatic hyperplasia. Digital and imaging findings were compared with biopsy outcomes. The study focused on patients in the gray zone of PSA levels.

Five of 34 patients had prostatic cancer, and two had PIN lesions. Four patients had prostatitis, and 23 had benign prostatic hyperplasia. PSA velocity increased in all patients with positive histology. Only 6 of 27 patients with negative histology showed PSA increases. Three of seven cancer patients had a PSAD of 0.15 or greater. Free/total PSA ratio remained below the cut-off in all cases. Gleason scores ranged from 2 to 4. These findings suggest that cancer can be detected in areas appearing normal on imaging.

The authors suggest that prostatic biopsy can detect tumors in areas that appear normal on transrectal ultrasound and digital exams. They propose that PSA velocity increases in patients with positive histology. The study confirms the diagnostic value of random biopsies in the gray zone of PSA levels. The authors suggest that PSAD and free/total PSA ratios may not reliably distinguish cancer from benign conditions. The study does not claim that imaging or exams are unnecessary. The authors propose that biopsies remain important in this diagnostic range. No definitive statement is made about replacing other diagnostic techniques. The authors suggest that further research is needed to define the role of biopsy relative to other methods.